Wells Fargo lowered the firm’s price target on Cabaletta Bio to $20 from $35 and keeps an Overweight rating on the shares. While the Gr4 ICANS case increases the risk on CABA-201, the firm thinks it fits its view patient selection is required for CAR T in I&I and learnings from this will better help flesh this criteria out.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio price target lowered to $25 from $30 at H.C. Wainwright
- Citi says Cabaletta views Grade 4 ICANS event as ‘potentially a one-off’
- Cabaletta Bio Unveils Updated Corporate Strategy Details
- Cabaletta Bio reports Q2 EPS (56c) consensus (55c)
- Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Questions or Comments about the article? Write to editor@tipranks.com